A USA company, Abbott, has received authorization from the U.S. Food and Drug Administration for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.

What makes this test so different is where it can be used: outside the four walls of a traditional hospital such as in the physicians’ office or urgent care clinics.

The test runs on a lightweight box (6.6 pounds and the size of a small toaster) that can sit in a variety of locations.

Because of its small size, it can be used in more non-traditional places where people can have their results in a matter of minutes.

They are ramping up production to deliver 50,000 ID NOW COVID-19 tests per day, beginning next week, to the U.S. healthcare system.

“Through the incredible work of teams across Abbott, we expect to deliver 50,000 COVID-19 tests per day to healthcare professionals on the front lines, where testing capabilities are needed most,” said Chris Scoggins, senior vice president, Rapid Diagnostics, Abbott